Jump to content
RemedySpot.com

Nucleoside Analogue Can Improve the Long-Term Prognosis of Patients with Hepatitis B Virus Infection-Associated Acute on Chronic Liver Failure

Rate this topic


Recommended Posts

Guest guest
Posted

Dig Dis Sci. 2010 May 29. [Epub ahead of print]

Nucleoside Analogue Can Improve the Long-Term Prognosis of Patients with

Hepatitis B Virus Infection-Associated Acute on Chronic Liver Failure.

Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P.

Center of Infectious Diseases, West China Hospital, West China School of

Medicine, Sichuan University, 37# Guoxue Lane, 610041, Chengdu, China.

Abstract

BACKGROUND: The prognosis of patients with hepatitis B virus (HBV)-associated

acute on chronic liver failure (ACLF) is extremely poor. AIM: This study was

designed to evaluate the efficacy and safety of nucleoside analogue treatment of

patients with HBV-associated ACLF. METHODS: We used a retrospective review of

eligible patients from April 2006 to December 2008. Eligible subjects received

0.5 mg entecavir daily until October 2009 (group A), 100 mg lamivudine daily

until October 2009 (group B), or no nucleoside analogue (group C). The primary

endpoints were three-month survival and the rate of recurrence of HBV-associated

ACLF. The secondary endpoints were HBV DNA levels, liver function, the model of

end-stage liver disease (MELD) score, and adverse events. RESULTS: A total of

104 consecutive patients were recruited, and 33, 34, and 37 patients were

randomly allocated to groups A, B, and C, respectively. Although no significant

difference in three-month survival was observed, levels of HBV DNA and rates of

recurrence of HBV-associated ACLF were lower. Liver function and MELD score were

not significantly improved despite significantly reduced HBV DNA levels.

CONCLUSIONS: These data indicated that nucleoside analogue treatment did not

improve the short-term prognosis of patients with HBV-associated ACLF although

it was efficacious and safe in the management of HBV DNA levels. Intriguingly

and importantly, continuous nucleoside analogue treatment can significantly

reduce the rate of recurrence, which might be indicative of the further benefit

of long-term survival.

PMID: 20512414 [PubMed - as supplied by publisher

_________________________________________________________________

The New Busy is not the old busy. Search, chat and e-mail from your inbox.

http://www.windowslive.com/campaign/thenewbusy?ocid=PID28326::T:WLMTAGL:ON:WL:en\

-US:WM_HMP:042010_3

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...